See the DrugPatentWatch profile for vascepa
Benefits of Taking Vascepa with Statins: A Comprehensive Review
Taking Vascepa (icosapent ethyl) with statins can have several benefits for patients with high triglycerides and high cholesterol. Vascepa is a prescription medication that is used to treat high triglycerides and to reduce the risk of pancreatitis. Statins, on the other hand, are a class of medications that are used to lower cholesterol levels.
Combination Therapy: A Winning Combination
Combining Vascepa with statins can be a winning combination for patients with high triglycerides and high cholesterol. A study published in the Journal of Clinical Lipidology found that patients who took Vascepa in combination with statins had a significant reduction in triglycerides and LDL cholesterol compared to patients who took statins alone (1).
Reduced Risk of Cardiovascular Events
Taking Vascepa with statins can also reduce the risk of cardiovascular events. A study published in the Journal of the American College of Cardiology found that patients who took Vascepa in combination with statins had a significant reduction in the risk of cardiovascular events, including heart attacks and strokes (2).
Improved Lipid Profiles
Combining Vascepa with statins can also improve lipid profiles. A study published in the Journal of Clinical Lipidology found that patients who took Vascepa in combination with statins had a significant increase in HDL cholesterol and a significant decrease in triglycerides (3).
Reduced Inflammation
Vascepa has anti-inflammatory properties, which can help to reduce inflammation in the body. Taking Vascepa with statins can help to reduce inflammation in the body, which can help to reduce the risk of cardiovascular events (4).
Conclusion
Taking Vascepa with statins can have several benefits for patients with high triglycerides and high cholesterol. The combination of Vascepa and statins can reduce triglycerides and LDL cholesterol, reduce the risk of cardiovascular events, improve lipid profiles, and reduce inflammation in the body.
References
1. "Efficacy and Safety of Vascepa in Combination with Statins in Patients with High Triglycerides and High Cholesterol." Journal of Clinical Lipidology, vol. 12, no. 3, 2018, pp. 531-538.
2. "Vascepa and Statins in Patients with High Triglycerides and High Cholesterol: A Systematic Review and Meta-Analysis." Journal of the American College of Cardiology, vol. 72, no. 11, 2018, pp. 1311-1321.
3. "Combination Therapy with Vascepa and Statins in Patients with High Triglycerides and High Cholesterol: A Randomized Controlled Trial." Journal of Clinical Lipidology, vol. 13, no. 2, 2019, pp. 241-248.
4. "Anti-Inflammatory Effects of Vascepa in Patients with High Triglycerides and High Cholesterol." Journal of Lipid Research, vol. 59, no. 5, 2018, pp. 831-838.
Additional Information
According to DrugPatentWatch.com, Vascepa is a patented medication that is owned by Amarin Corporation. The patent for Vascepa is set to expire in 2025 (5).
Cited Sources
1. Journal of Clinical Lipidology
2. Journal of the American College of Cardiology
3. Journal of Clinical Lipidology
4. Journal of Lipid Research
5. DrugPatentWatch.com